Geron (NASDAQ:GERN – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01), Zacks reports. Geron had a negative net margin of 34.17% and a negative return on equity of 24.06%. The company had revenue of $57.48 million for the quarter, compared to the consensus estimate of $55.30 million.
Here are the key takeaways from Geron’s conference call:
- RYTELO net revenue rose 17% year over year to $57.5 million in the second quarter, while first-half revenue increased approximately 24% year over year.
- RYTELO demand grew 5% sequentially, prescribing accounts increased 8% to approximately 1,575, and the company expects 2026 net product revenue of $220 million-$240 million to land at the mid-to-high end of guidance.
- Management cited encouraging real-world evidence in lower-risk MDS that was generally consistent with the Phase III IMerge trial, supporting RYTELO adoption—particularly in earlier lines of therapy and community treatment centers.
- Geron ended the quarter with $327 million in cash, equivalents, restricted cash, and marketable securities, while maintaining 2026 operating expense guidance of $230 million-$240 million and reporting a 4% first-half decrease in operating expenses.
- The company is evaluating a modification to the interim event threshold for the Phase III IMpactMF myelofibrosis trial after discussions with regulators; although timelines remain unchanged, the base case still calls for final overall-survival analysis in the second half of 2028.
Geron Trading Down 4.8%
Shares of NASDAQ:GERN traded down $0.07 during midday trading on Friday, reaching $1.50. The company had a trading volume of 5,427,613 shares, compared to its average volume of 15,100,546. The company has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $1.46. The firm has a market cap of $959.07 million, a price-to-earnings ratio of -13.57 and a beta of 0.61. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.96 and a current ratio of 6.78. Geron has a 1-year low of $1.04 and a 1-year high of $2.01.
Institutional Inflows and Outflows
More Geron News
Here are the key news stories impacting Geron this week:
- Positive Sentiment: Geron reported record second-quarter revenue of $57.48 million, exceeding analysts’ $55.30 million forecast, as commercial demand for Rytelo helped drive growth. The revenue beat is a constructive signal for the company’s marketed-product trajectory. Geron adds a record 16% as Rytelo drives Q2 revenue beat
- Positive Sentiment: Traders purchased a large volume of Geron call options, indicating increased speculative or bullish interest in the stock. Options activity does not guarantee a sustained move, but it can contribute to near-term trading momentum. Stock Traders Buy Large Volume of Geron Call Options
- Neutral Sentiment: Analyst opinions remain mixed. Coverage continues to focus on Geron’s transition from a loss-making biotech to a potentially profitable commercial-stage company, making future Rytelo sales and execution key valuation drivers. Analysts’ Opinions Are Mixed on These Healthcare Stocks
- Negative Sentiment: Geron’s second-quarter adjusted loss of $0.02 per share missed the $0.01 consensus estimate, underscoring that revenue growth has not yet translated into profitability.
- Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.05 from a loss of $0.02 and cut estimates for FY2027 through FY2030. The reductions—particularly the FY2030 forecast decline to $0.55 from $0.59—signal greater caution about the pace of Geron’s future earnings growth.
Analyst Ratings Changes
Separately, Weiss Ratings cut Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.
View Our Latest Stock Analysis on GERN
Geron Company Profile
Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.
The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than Geron
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
